Mark S Freedman. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Brain/pathologyDisease ProgressionDrug Administration ScheduleGlatiramer AcetateHumansImmunologic Factors/therapeutic useImmunosuppressive Agents/therapeutic useInterferon-beta/therapeutic useMagnetic Resonance ImagingMultiple Sclerosis/diagnosisMultiple Sclerosis/drug therapyMultiple Sclerosis/physiopathologyPeptides/therapeutic useTime Factors
Substances: See more » Immunologic FactorsImmunosuppressive AgentsPeptidesGlatiramer AcetateInterferon-beta
Year: 2009 PMID: 19808740 DOI: 10.1177/1352458509345920
Source DB: PubMed Journal: Mult Scler ISSN: 1352-4585 Impact factor: 6.312